Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline plc    GSK   GB0009252882


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : GSK and Sanofi start with new COVID-19 vaccine study after setback

02/22/2021 | 08:03am EST
FILE PHOTO: Sanofi logo is seen in Paris

(Reuters) - GlaxoSmithKline and Sanofi on Monday said they had started a new clinical trial of their protein-based COVID-19 vaccine candidate, reviving their efforts against the pandemic after a setback in December delayed the shot's launch.

The British and French drugmakers aim to reach final testing in the second quarter, and if the results are conclusive, hope to see the vaccine approved by the fourth quarter after having initially targeted the first half of this year.

In December, the two groups stunned investors when they said their vaccine would be delayed towards the end of 2021 after clinical trials showed an insufficient immune response in older people.

Disappointing results were probably caused by an inadequate concentration of the antigen used in the vaccine, Sanofi and GSK said, adding that Sanofi has also started work against new coronavirus variants to help plan their next steps.

Global coronavirus infections have exceeded 110 million as highly transmissible variants of the virus are prompting vaccine developers and governments to tweak their testing and immunisation strategies.

GSK and Sanofi's vaccine candidate uses the same recombinant protein-based technology as one of Sanofi's seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

"Over the past few weeks, our teams have worked to refine the antigen formulation of our recombinant-protein vaccine," Thomas Triomphe, executive vice president and head of Sanofi Pasteur, said in a statement.

The new mid-stage trial will evaluate the safety, tolerability and immune response of the vaccine in 720 healthy adults across the United States, Honduras and Panama and test two injections given 21 days apart.

Sanofi and GSK have secured deals to supply their vaccine to the European Union, Britain, Canada and the United States. It also plans to provide shots to the World Health Organization's COVAX programme.

To appease critics after the delay, Sanofi said earlier this year it had agreed to fill and pack millions of doses of the Pfizer/BioNTech vaccine from July.

Sanofi is also working with Translate Bio on another COVID-19 vaccine candidate based on mRNA technology.

(Reporting by Pushkala Aripaka in Bengaluru and Matthias Blamont in Paris; editing by Jason Neely and Barbara Lewis)

By Pushkala Aripaka and Matthias Blamont

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 0.60% 1198 Delayed Quote.-10.54%
SANOFI 0.82% 76.42 Real-time Quote.-3.68%
03:33pGLAXOSMITHKLINE  : Buy rating from Goldman Sachs
12:01aGLAXOSMITHKLINE  : Dostarlimab Endometrial Cancer Treatment Recommended for Appr..
02/26GLAXOSMITHKLINE  : GSK receives CHMP positive opinion recommending approval of d..
02/25GLAXOSMITHKLINE  : Study on Otilimab for Treatment of Hospitalized Patients with..
02/25GLAXOSMITHKLINE  : Study on Otilimab for Treatment of Hospitalized Adult Patient..
02/25GLAXOSMITHKLINE  : GSK to Assess Efficacy of COVID-19 Monoclonal Antibody Treatm..
02/25GSK narrows focus on elderly in trial to treat pneumonia from COVID-19
02/25GLAXOSMITHKLINE  : Covid-19 Antibody Study Didn't Meet Primary Endpoint
02/25GLAXOSMITHKLINE  : GSK announces results evaluating its investigational monoclon..
02/24GRANULES INDIA  : Gets US FDA Nod For Migraine Treatment Drug
More news
Sales 2020 34 076 M 47 455 M 47 455 M
Net income 2020 4 894 M 6 816 M 6 816 M
Net Debt 2020 22 676 M 31 579 M 31 579 M
P/E ratio 2020 12,4x
Yield 2020 6,66%
Capitalization 59 926 M 83 586 M 83 456 M
EV / Sales 2020 2,42x
EV / Sales 2021 2,40x
Nbr of Employees 99 437
Free-Float 92,5%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | GSK | GB0009252882 | MarketScreener
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 1 540,00 GBX
Last Close Price 1 200,60 GBX
Spread / Highest target 74,9%
Spread / Average Target 28,3%
Spread / Lowest Target -19,7%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON0.69%416 541
ROCHE HOLDING AG-3.58%280 845
NOVARTIS AG-6.53%194 250
ABBVIE INC.0.55%190 256
PFIZER INC.-9.02%186 852